Better Health, Brighter Future
Growth & Emerging Markets Business Unit
Headquartered in Singapore, Takeda's Growth & Emerging Markets Business Unit (GEM BU) has presencearound 30 countries and territories, which are organized into a Stand-Alone Core Market - Brazil, two Core Hubs - SAM & TAS and three Multi-Country Organizations (MCOs) – I-SEA, TuRC & UMEA*.
About Us
In line with Takeda’s global strategy, GEM BU is focused on delivering highly innovative medicines to patients living with complex and rare diseases in its five key business areas – Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology and Neuroscience.
We strive to do so via an ‘Access First’ mindset that aims to ‘fast track’ patient access to life-transforming medicines across a region of over
5 billion people, which represents almost 65% of the world population, via accelerating product launches and the expansion of appropriate local-specific initiatives via Takeda’s global Access to Medicines programs.
GEM BU is committed to working with strategic partners across the region, including governments, patient organizations and healthcare regulators, to accelerate patient access, address unmet patient needs, drive future growth, and ensure a sustainable business.
Recognized as a 'Top Employer'
The BU aspires to be viewed as 'Best in Class' in the eyes of patients, customers and its own employees. Over the recent years, many of its local offices across the region have been externally recognized as a ‘Top Employer’ by the Top Employer Institute.
*SAM – South Cone, Andean & Mexico
TAS – Taiwan, Australia & South Korea
I-SEA – India & South East Asia
TuRC – Turkey, Russia & CIS countries
UMEA – Ukraine, Middle East & Africa
Contact Us
Address:
TAKEDA PHARMACEUTICALS INTERNATIONAL AG SINGAPORE BRANCH
8 Marina Boulevard, #15-01 Marina Bay Financial Centre, Singapore 018981
Tel: +65-6808-9500
Fax: +65-6808-9525
